Navigation Links
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
Date:9/19/2013

afety and dosing profile over current therapies
  • Studies by the National Cancer Institute and DelMar have shown VAL-083 to have activity against a range of cancers, including glioblastoma
  • DelMar is conducting a Phase I/II clinical trial for VAL-083 at UC San Francisco and the Sarah Cannon Research Institute in Nashville, Tennessee and Sarasota, Florida
  • VAL-083 has received orphan drug designation in Europe and the U.S.
  • Additional Information:

    About DelMar Pharmaceuticals

    Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

    For more information, please visit www.delmarpharma.com or follow us on Twitter

    SOURCE DelMar Pharmaceuticals
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
    (Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
    (Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
    ... Belgium, December 12, 2011 The peer ... of a clinical trial demonstrating the sedative action of the ... whose abstract is available from the US National Libretry of ... http://www.ncbi.nlm.nih.gov/pubmed/22035386 The results show, ...
    ... FRANCISCO, Calif., Dec. 10, 2011  Onyx Pharmaceuticals, Inc. (Nasdaq: ... poster presentations of single-agent carfilzomib, a next generation proteasome ... at the 53rd American Society of Hematology (ASH) Annual ... expanded data set supports our belief in the potential ...
    Cached Medicine Technology:Insomnia: A No-Drug Solution? 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 5Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 6
    (Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
    (Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
    (Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
    (Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
    (Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
    Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
    ... a recent study that came out in the journal Environmental ... plastics on human beings. ,Bisphenol-A (BPA) is a ... grade materials for making air tight containers, drinking water bottles, ... of Medicine did the study to find out about the ...
    ... that spreads through mosquito bites, among other things, did not ... of Nature Medicine scientists have shown a successful treatment on ... developed an antibody that can successfully fight the virus. The ... naturally against this virus and in turn never get affected ...
    ... study made by researchers of UK, scientists have found that ... the blood of the passengers. ,The study was done ... today, do have any effect on the health of the ... peripheral oxygen saturation and pulse rate of 84 passengers, aged ...
    ... cure people suffering from hay fever by teaching them self-hypnosis.//,The ... curing allergic reactions. 79 patients of an average age of ... or pollen were taken in the study. All these people ... years. Random parallel group was used as control for the ...
    ... to be a risk factor for multiple sclerosis. New ... more in people suffering from multiple sclerosis. ,In ... of medicine, researchers had been able to associate habitual ... sclerosis. In a study comprising of 201 cases of ...
    ... addiction is a problem because the addicts find it hard ... this type of behavior may be that drugs affect the ... towards other rewards of life, like eating and fulfilling of ... treat drug addiction may be a surgical procedure by which ...
    Cached Medicine News:
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: